Effects of sitagliptin beyond glycemic control: focus on quality of life.
Effects of sitagliptin beyond glycemic control: focus on quality of life.
复制标题
西他列汀超出血糖控制的影响：关注生活质量。
DOI：
10.1186/1475-2840-12-35
复制
发表时间：
2013-02-21
影响因子：
9.3
通讯作者：
S-DOG investigators
中科院分区：
文献类型：
--
作者：
Sakamoto Y;Oyama J;Ikeda H;Kuroki S;Gondo S;Iwamoto T;Uchida Y;Kodama K;Hiwatashi A;Shimomura M;Taguchi I;Inoue T;Node K;S-DOG investigators
近年来，研究发现肠促胰岛素激素，包括胰高血糖素样肽-1（GLP-1）类似物和二肽基肽酶-4（DPP-4）抑制剂，可调节糖代谢。本研究旨在阐明DPP-4抑制剂在日本临床使用的疗效和安全性。本研究设计为前瞻性、开放标签、多中心试验。尽管接受了医疗饮食、治疗性运动和/或药物治疗，但血糖水平较差（HbA 1c ≥ 6.2%）的2型糖尿病（T2 DM）患者有资格参加本研究。受试者接受50至100 mg DPP-4抑制剂西格列汀，每日一次，持续12个月。入组了188例受试者。西格列汀治疗12个月后，HbA 1c水平下降（7.65% ± 1.32%至7.05% ± 1.10%，p < 0.001），空腹血糖（FPG）下降（145 ± 52 mg/dl至129 ± 43 mg/dl，p = 0.005）。达到的血糖控制率（根据日本糖尿病学会指南）显著增加。血压和血清甘油三酯和总胆固醇水平显着下降。此外，匹兹堡睡眠质量指数（PSQI）和糖尿病症状评分显着改善。23例受试者（11%）发生了低血糖和意识丧失等不良事件。这些结果表明，DPP-4抑制剂的作用不仅可改善血糖控制，还可改善血压、血脂和生活质量（QOL）。西格列汀是T2 DM患者综合治疗的理想药物。
Recently, incretin hormones, including glucagon-like peptide-1 (GLP-1) analogue and dipeptidyl peptidase-4 (DPP-4) inhibitor, have been found to regulate glucose metabolism. The aim of this study was to elucidate the efficacy and safety of the clinical usage of DPP-4 inhibitors in Japan. This study was designed as a prospective, open-label, multi-center trial. Patients with diabetes mellitus type 2 (T2DM) with poor glycemic profiles (HbA1c ≥ 6.2%) in spite of receiving a medical diet, therapeutic exercise, and/or medications were eligible for this study. The participants received 50 to 100 mg of the DPP-4 inhibitor sitagliptin once daily for 12 months. One hundred and eighty-eight subjects were enrolled. After 12 months of sitagliptin treatment, HbA1c levels decreased (7.65% ± 1.32% to 7.05% ± 1.10%, p < 0.001) as well as fasting plasma glucose (FPG) (145 ± 52 mg/dl to 129 ± 43 mg/dl, p = 0.005). The rate of glycemic control achieved (in accordance with the guidelines of the Japanese Diabetes Society) significantly increased. Blood pressure and serum levels of triglycerides and total cholesterol decreased significantly. Furthermore, the Pittsburgh Sleep Quality Index (PSQI) and Diabetes Symptomatic Scores improved significantly. Adverse events such as hypoglycemia and loss of consciousness occurred in twenty three subjects (11%). These results suggest that the actions of DPP-4 inhibitors improve not only glycemic control, but also blood pressure, lipid profiles, and quality of life (QOL). Sitagliptin is a sound agent for use in the comprehensive treatment of patients with T2DM.
登录
查看更多内容
影响因子：
4.7
作者：
Carpenter, JS;Andrykowski, MA
通讯作者：
Andrykowski, MA
影响因子：
3.3
作者：
Brooks, R
通讯作者：
Brooks, R
影响因子：
5.8
作者：
Gutzwiller, JP;Tschopp, S;Beglinger, C
通讯作者：
Beglinger, C
影响因子：
8.2
作者：
de Heer, J.;Rasmussen, C.;Holst, J. J.
通讯作者：
Holst, J. J.
影响因子：
16.2
作者：
GREENE, DA;SIMA, AAF;LATTIMER, SA
通讯作者：
LATTIMER, SA